108 related articles for article (PubMed ID: 23570202)
1. The relationship between thrombin and platelets: linking vessel injury to thrombosis and inflammation.
Schneider DJ
J Invasive Cardiol; 2004 Dec; 16 Suppl G():8-11. PubMed ID: 23570202
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin, thrombin and platelets: clinical implications and future directions.
Becker R; Butenas S; Carr M; Jaffer F; Kleiman NS; Marmur JD; Schneider DJ; Spiess BD; Steinhubl SR; Weitz JI
J Invasive Cardiol; 2003 Aug; Suppl():2-15. PubMed ID: 23570139
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1995 Jul; 74(1):464-72. PubMed ID: 8578508
[No Abstract] [Full Text] [Related]
4. Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial.
Khanna V; Shahzad A; Thayalasamy K; Kemp I; Mars C; Cooper R; Roome C; Wilson K; Harris S; Stables R; Curzen N
Thromb Res; 2018 Dec; 172():36-43. PubMed ID: 30359789
[TBL] [Abstract][Full Text] [Related]
5. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
Zokai K; Piazolo L; Harenberg J
Semin Thromb Hemost; 2001 Oct; 27(5):531-6. PubMed ID: 11668424
[TBL] [Abstract][Full Text] [Related]
6. Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation.
Schneider DJ; Sobel BE
Coron Artery Dis; 2009 Mar; 20(2):175-8. PubMed ID: 19194284
[TBL] [Abstract][Full Text] [Related]
7. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
[TBL] [Abstract][Full Text] [Related]
8. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
Maroo A; Lincoff AM
Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
[TBL] [Abstract][Full Text] [Related]
9. [Bivalirudin: a direct thrombin inhibitor in percutaneous coronary interventions].
Hansen PR
Ugeskr Laeger; 2006 Sep; 168(38):3207-9. PubMed ID: 17026893
[TBL] [Abstract][Full Text] [Related]
10. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin: a new promising direct antithrombin.
Bhambhani A; Meier B
Indian Heart J; 2007; 59(3):288-94. PubMed ID: 19124943
[TBL] [Abstract][Full Text] [Related]
12. Modulating platelet function with selective thrombin inhibitors.
Verstraete M
Haemostasis; 1996 Oct; 26 Suppl 4():70-7. PubMed ID: 8979113
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin: an anticoagulant option for percutaneous coronary intervention.
Bates ER
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):153-62. PubMed ID: 15151464
[TBL] [Abstract][Full Text] [Related]
14. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
[TBL] [Abstract][Full Text] [Related]
15. Platelet protagonist/antagonist: understanding the distinguishing characteristics of anticoagulants.
Schneider DJ
Rev Cardiovasc Med; 2006; 7 Suppl 3():S3-11. PubMed ID: 17224882
[TBL] [Abstract][Full Text] [Related]
16. Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.
Yehudai L; Feit F
J Interv Cardiol; 2006 Oct; 19(5):464-9. PubMed ID: 17020572
[TBL] [Abstract][Full Text] [Related]
17. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
Zhao L; Bath PM; May J; Lösche W; Heptinstall S
Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
[TBL] [Abstract][Full Text] [Related]
18. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
[TBL] [Abstract][Full Text] [Related]
19. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
20. Strategies for inhibiting the effects of thrombin.
Harker LA
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
